Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
作者信息
Wahedna I, Wisniewski A S, Tattersfield A E
机构信息
Respiratory Medicine Unit, City Hospital, Nottingham.
出版信息
Br J Clin Pharmacol. 1991 Oct;32(4):512-5. doi: 10.1111/j.1365-2125.1991.tb03941.x.
Abstract
We have studied the effect of RG 12525, an oral leukotriene D4 (LTD4) antagonist, on LTD4-induced bronchoconstriction in eight male subjects with mild asthma (baseline FEV1 greater than 80% predicted) in a double-blind, placebo-controlled fashion. RG 12525 800 mg displaced the dose-response curve for LTD4 to the right. The mean (95% confidence intervals) difference in log PC20FEV1 following RG 12525 and placebo was 2.88 (1.61, 4.17) doubling doses of LTD4 (P less than 0.01), a 7.5 fold difference. We conclude that RG 12525 when administered orally is an effective LTD4 antagonist in subjects with mild asthma.
摘要
相似文献
1
Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
Br J Clin Pharmacol. 1991 Oct;32(4):512-5. doi: 10.1111/j.1365-2125.1991.tb03941.x.
2
MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.
Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):617-21. doi: 10.1164/ajrccm/144.3_Pt_1.617.
3
The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics.
Pulm Pharmacol. 1991;4(1):37-42. doi: 10.1016/0952-0600(91)90037-4.
4
Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects.
J Pharmacol Exp Ther. 1988 Aug;246(2):732-8.
5
Reproducibility of leukotriene D4 inhalation challenge in asthmatics. Effect of a novel leukotriene D4/E4-antagonist (SR 2640) on leukotriene D4-induced bronchoconstriction.
Allergy. 1991 Jul;46(5):355-61. doi: 10.1111/j.1398-9995.1991.tb00598.x.
6
Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.
Clin Pharmacol Ther. 1993 Oct;54(4):430-6. doi: 10.1038/clpt.1993.170.
7
Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects.
J Allergy Clin Immunol. 1989 May;83(5):939-44. doi: 10.1016/0091-6749(89)90109-7.
8
Effect of RG 12525, a new leukotriene antagonist, on pulmonary function of asthmatic adults.
Ann Allergy. 1994 Apr;72(4):348-52.
9
Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
Clin Pharmacol Ther. 1997 Jan;61(1):83-92. doi: 10.1016/S0009-9236(97)90184-3.
10
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.
N Engl J Med. 1990 Dec 20;323(25):1736-9. doi: 10.1056/NEJM199012203232504.
引用本文的文献
1
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD002314. doi: 10.1002/14651858.CD002314.pub3.
2
Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma.
Cochrane Database Syst Rev. 2004;2004(2):CD003133. doi: 10.1002/14651858.CD003133.pub2.
3
Clinical evidence with montelukast in the management of chronic childhood asthma.
Drugs. 2000;59 Suppl 1:29-34; discussion 43-5. doi: 10.2165/00003495-200059001-00005.
4
Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions.
Springer Semin Immunopathol. 1993;15(1):37-50. doi: 10.1007/BF00204625.
本文引用的文献
1
Bronchial hyperreactivity to leucotriene D4 and histamine in exogenous asthma.
Br Med J (Clin Res Ed). 1985 May 18;290(6480):1468-71. doi: 10.1136/bmj.290.6480.1468.
2
The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man.
J Allergy Clin Immunol. 1987 May;79(5):816-21. doi: 10.1016/0091-6749(87)90215-6.
3
Dose-related antagonism of leukotriene D4-induced bronchoconstriction by p.o. administration of LY-171883 in nonasthmatic subjects.
J Pharmacol Exp Ther. 1988 Aug;246(2):732-8.
4
The effect of RG 12525 on leukotriene D4-mediated pulmonary responses in guinea pigs.
Agents Actions. 1989 Jun;27(3-4):316-8. doi: 10.1007/BF01972809.
5
Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis.
Lancet. 1989 Mar 18;1(8638):584-8. doi: 10.1016/s0140-6736(89)91611-5.
6
A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma.
Am Rev Respir Dis. 1989 Nov;140(5):1336-9. doi: 10.1164/ajrccm/140.5.1336.
7
Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases.
J Allergy Clin Immunol. 1989 Jul;84(1):19-26. doi: 10.1016/0091-6749(89)90173-5.
8
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
N Engl J Med. 1990 Dec 20;323(25):1740-4. doi: 10.1056/NEJM199012203232505.
9
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.
N Engl J Med. 1990 Dec 20;323(25):1736-9. doi: 10.1056/NEJM199012203232504.
10
Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.
Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):988-92. doi: 10.1164/ajrccm/141.4_Pt_1.988.
Zotero 插件